What Edwards Lifesciences's Quarter ended Sep 30, 2026 10-Q says: 4 signals
Edwards Lifesciences filed its latest 10-Q with the SEC on Nov 4, 2026. It discusses compliance burden, goodwill impairment and product launch.
Public (EW)Medical Equipment Manufacturing10,000+ employeesedwards.comLinkedIn
Get Edwards Lifesciences' live signals in Claude or ChatGPT, or by API
What changed at Edwards Lifesciences this week? Use Autobound signals for edwards.com.- Filed
- Nov 4, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 12
Source: Autobound Signal API · 68 signals tracked for Edwards Lifesciences · updated
10-Q · latest 10
What Edwards Lifesciences's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 4 signals
Edwards Lifesciences records $220.2 million impairment on in-process R&D intangible asset
Edwards Lifesciences recognized $220.2 million in intangible and long-lived asset impairment charges during the three and nine months ended September 30, 2026, primarily related to the full impairment of an in-process R&D asset.
$220.2M
impairment of a certain in-process research and development asset
FDA Approvals for PASCAL Precision and AUTUS Size-Adjustable Valve Received in October 2026
Edwards Lifesciences received FDA approval for the PASCAL Precision System for tricuspid valve repair and the AUTUS Size-Adjustable Valve for pediatric patients in October 2026.
PASCAL Precision SystemAUTUS Size-Adjustable Valve
During the nine months ended September 30, 2026, the company recognized $2.0 million in severance tied to realignment initiatives and $8.7 million related to contract terminations from acquisitions.
California tax legislation prompts $174.4 million deferred tax asset valuation allowance
A California budget enactment on June 29, 2026 permanently limited business tax credit utilization, forcing a $174.4 million valuation allowance against deferred tax assets in Q2 and Q3 2026.
$174.4M
valuation allowance recorded against deferred tax assets due to California budget legislation
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 4 signals
Edwards Lifesciences acquired Autus Valve Technologies for $128.9 million plus contingent milestones
Edwards Lifesciences acquired Autus Valve Technologies, Inc.
$128.9M
total consideration for the acquisition of Autus Valve Technologies, Inc.
IRS issues Final NOPAs proposing over $2.0 billion increase to U.S. taxable income
During Q2 2026, the IRS issued two Final Notices of Proposed Adjustment proposing to increase taxable income by $233.5 million for 2018 and by $625.3 million, $530.7 million, and $683.6 million across 2018-2020 for transfer pricing on Surgical and TAVR licenses.
$233.5M
proposed increase to U.S. taxable income for 2018 under first Final NOPA
Capital expenditures increased to $131.8 million in the first six months of 2026
Edwards Lifesciences invested $131.8 million in capital expenditures during the six months ended June 30, 2026, up from $105.3 million in the prior year period.
$131.8M
capital expenditures for the six months ended June 30, 2026
Pillar Two global minimum tax expected to add $50.0 million in tax expense
Edwards Lifesciences expects OECD Pillar Two provisions to result in approximately $50.0 million of additional tax expense in 2026 prior to offsets under current law.
$50M
expected additional tax expense from Pillar Two provisions in 2026
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 4 signals
Edwards Lifesciences acquired Autus Valve Technologies for $128.9 million in February 2026
Edwards Lifesciences completed the acquisition of Autus Valve Technologies, Inc.
$128.9M
total consideration to acquire Autus Valve Technologies, Inc.
FDA approved SAPIEN 3 transcatheter pulmonic valve delivery system in January 2026
Edwards received FDA approval in January 2026 for the SAPIEN 3 transcatheter pulmonic valve delivery system for pediatric and adult congenital heart disease patients.
Showing 10 of 12 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Edwards Lifesciences earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Q3 sales rise 11.2% to $1.72B with 78.7% gross marginThird quarter sales reached $1.72 billion representing 11.2% year-over-year underlying growth, while adjusted gross profit margin expanded to 78.7% from 77.9%. Operating profit margin achieved 30.3% and adjusted EPS reached $0.80. The company's performance signals strong cash generation and budget capacity for commercial and operational vendors. | |
| Full-year sales growth raised to 11.5% and EPS to $3.01Management raised full-year 2026 sales growth guidance to approximately 11.5% and adjusted EPS to $2.97-$3.05 (midpoint $3.01, representing 18% growth). TAVR full-year guidance was raised to 9%-9.5% and TMTT expectations increased to $780M-$790M. Expanding operational and commercial budgets will support these upgraded delivery targets. | |
| TAVR global sales grow 8.8% to $1.2B in third quarterGlobal TAVR procedure growth drove revenue of $1.2 billion, up 8.8% year-over-year with balanced performance across the U.S. and OUS markets. ASPs remained stable globally while procedure volumes accelerated exiting the quarter. Sales teams targeting cath lab workflows and structural heart infrastructure can capitalize on continuing procedural volume expansion. | |
| Annualized Boston Scientific European exit while stabilizing TAVR shareEdwards noted that benefits from Boston Scientific's European exit have annualized after four quarters of share gains. Going forward, management expects TAVR growth to rely primarily on market procedure volume rather than market share expansion against competitors. | |
| TAVR market share gains plateau after Boston Scientific exitThe company marked over four consecutive quarters of modest TAVR share gains following Boston Scientific's May 2025 exit from Europe and OUS markets. While sequential share has now stabilized, future growth will tilt toward underlying market procedure volume expansion and expanded indications rather than further competitor displacement. Vendors helping optimize patient intake and clinical... | |
| Five structural heart therapy approvals expand portfolio commercializationThe company secured 5 therapy approvals over recent months, including U.S. approvals for PASCAL Ace with Capture Clarity, PASCAL Precision for tricuspid regurgitation, and pediatric pulmonary valve AUTUS. Commercial teams are executing major rollouts for Capture Clarity and ECLIPTIS while expanding EVOQUE transjugular access in the U.S. and Europe. These commercial introductions require... |
Signal API · MCP
Track Edwards Lifesciences with the Signal API
One POST /v1/companies/enrich call with edwards.com returns Edwards Lifesciences 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"edwards.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Edwards Lifesciences 10-Q
When did Edwards Lifesciences file its latest 10-Q?
What did Edwards Lifesciences disclose in its latest 10-Q?
What did Edwards Lifesciences say on its recent earnings calls?
Where can I read Edwards Lifesciences's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .